Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zushima total coumarin is a standardized pharmaceutical extract derived from the bark or roots of *Daphne giraldii* Nitsche, a plant used in traditional Chinese medicine (Zushima). Developed by the Tianjin Institute of Pharmaceutical Research, this extract is enriched with bioactive coumarin compounds, including daphnetin and umbelliferone. It is primarily developed for the treatment of osteoarthritis and rheumatoid arthritis. The drug exhibits significant anti-inflammatory and analgesic properties by inhibiting the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), and by modulating the NF-κB signaling pathway. These actions help to reduce joint pain, swelling, and inflammation, potentially mitigating the progression of joint damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zushima total coumarin.